Maria Gheorghe | Public Health & Epidemiology | Best Researcher Award

Ms. Maria Gheorghe | Public Health & Epidemiology | Best Researcher Award

Director at Pfizer Inc, Romania

Maria Gheorghe is an accomplished expert in health economics and outcomes research (HEOR) with over 14 years of impactful contributions spanning academia, research institutions, and the pharmaceutical industry. Currently serving as Director of Global HTA, Value and Evidence at Pfizer Inc., she has led high-stakes initiatives in antimicrobial resistance, oncology, and vaccine access. Her career reflects a commitment to evidence-based healthcare, strategic market access, and policy transformation at both national and international levels.

profile

orcid

Education

Maria Gheorghe holds a PhD in Health Economics from Erasmus University Rotterdam, where her doctoral work focused on quantitative approaches to monitoring population quality of life, particularly modeling and evaluating health utility data. She also earned an MSc in Applied Mathematics from Delft University of Technology, where she explored advanced Bayesian methods in reservoir simulation. Her academic foundation began with a BSc in Economics, majoring in Cybernetics, Statistics, and Economics, from the Academy of Economic Studies in Bucharest. This combination of mathematical rigor and economic insight has uniquely positioned her to address complex health policy challenges.

Professional Experience

Maria’s career is marked by a progressive trajectory through key roles in industry and academia. Since June 2022, she has led global value and evidence generation strategies at Pfizer for the launch of EMBLAVEO, a next-generation anti-infective. She has been instrumental in coordinating cross-functional global teams and external stakeholders to secure optimal pricing and reimbursement frameworks across various healthcare systems. Prior to this, she contributed to oncology strategy, particularly supporting the global launch of Talzenna + Xtandi for metastatic castration-sensitive prostate cancer (mCSPC). From 2019 to 2022, she held national responsibilities as Health & Value Manager for Pfizer Romania, where she led the market access strategies for Eliquis, Paxlovid, and hospital brands. Earlier roles at Sanofi in market access and public affairs allowed her to shape reimbursement policies and build influential partnerships. Her formative experience as a researcher at Erasmus School of Health Policy and Management laid the groundwork for her methodical and evidence-driven approach to health economics.

Research Interests

Maria’s research interests span real-world evidence, cost-effectiveness modeling, and antimicrobial resistance policy. She is particularly passionate about bridging the gap between epidemiological modeling and reimbursement systems, advancing HTA frameworks that integrate the societal value of novel therapeutics. Her recent work leverages machine learning and big data to inform pricing models for anti-infectives and supports innovative reimbursement agreements based on value-based healthcare principles.

Awards and Recognition

Maria has earned significant recognition for her strategic leadership and research excellence. She played a pivotal role in the UK’s innovative reimbursement scheme for anti-infectives—a global case study in AMR policy reform. She has also been commended internally at Pfizer for her contributions to cross-functional evidence planning and real-world data integration. Her academic achievements include graduating top of her MSc cohort at Delft and securing competitive research roles across Europe.

Selected Publications

Gheorghe M. et al. (2020). Economic evaluation of novel antibiotics: challenges and recommendations. Value in Health. Cited by 34 articles.

Gheorghe M. et al. (2019). Modeling transmission in cost-effectiveness studies: the case of antimicrobial resistance. Pharmacoeconomics. Cited by 21 articles.

Gheorghe M. et al. (2018). Quality of life trajectories in chronic disease populations: a longitudinal analysis. Health Economics. Cited by 16 articles.

Gheorghe M. et al. (2017). Bayesian approaches in population health modeling. Journal of Health Services Research & Policy. Cited by 12 articles.

Gheorghe M. et al. (2016). Comparative methods for population-level health utility estimation. European Journal of Health Economics. Cited by 10 articles.

Gheorghe M. et al. (2015). A meta-analysis of EQ-5D values across disease groups. International Journal of Technology Assessment in Health Care. Cited by 9 articles.

Gheorghe M. et al. (2014). Cost-effectiveness of vaccines in emerging markets. Vaccine. Cited by 17 articles.

Conclusion

Maria Gheorghe embodies the qualities of a top-tier researcher—intellectual excellence, strategic impact, innovation in health policy, and a commitment to public health advancement. Her accomplishments in research, leadership in evidence-based strategies, and contributions to global health challenges make her a highly deserving recipient of the Best Researcher Award.

Fani Pantouli | Infectious Diseases | Best Researcher Award

Dr. Fani Pantouli | Infectious Diseases | Best Researcher Award

Post-Doctoral Fellow at Cleveland Clinic, United States

Dr. Fani Pantouli is a highly accomplished neuroscientist and biomedical researcher with over a decade of multidisciplinary experience in neuroscience, immunology, oncology, and pharmacology. With a career devoted to preclinical and translational studies, she has played a pivotal role in advancing therapeutic and vaccine research. Her work integrates in vivo and in vitro models, cellular and molecular assay design, immunophenotyping, and tumor modeling. Adept in laboratory innovation and scientific collaboration, Dr. Pantouli is recognized for her contributions to understanding complex disease mechanisms and developing safer, more effective therapeutic interventions. Her fluency in Greek and proficiency in English, along with foundational skills in German and French, reflect her international orientation and adaptability in global research initiatives.

profile

scopus

Education

Dr. Pantouli earned her PhD in Neuropharmacology from the University of Surrey and St. George’s University of London between 2014 and 2017. Her doctoral work focused on therapeutic approaches for autism spectrum disorder (ASD), with groundbreaking investigations into oxytocin-based interventions. She holds a Master of Science in Molecular Neuroscience from the University of Bristol (2011) and a Bachelor of Science (Honours) in Biomedical Science from the University of Bedfordshire (2010). Complementing her formal education, she has undertaken professional development through courses such as Adaptive Immunity at Imperial College London, Good Clinical Practice certification, and statistical analysis in clinical research through the University of Cape Town.

Experience

Dr. Pantouli currently serves as a Postdoctoral Fellow in Vaccine Development at Cleveland Clinic Florida’s Research and Innovation Center. There, she investigates T-cell immunity, cytokine profiling, and vaccine efficacy using advanced in vitro models against SARS-CoV-2, RSV, and HMPV. She collaborates on a major ARPA-H funded project integrating AI tools for monoclonal antibody screening. Previously, as a Postdoctoral Fellow in the same institute’s Cancer Research Lab, she developed head and neck squamous cell carcinoma mouse models to study p53-targeted therapies. Her postdoctoral tenure at Scripps Research Institute spanned four years, where she contributed to the development of novel, side-effect-reducing opioid therapeutics through behavioral pharmacology, receptor screening, and drug metabolism profiling. Earlier academic roles include doctoral research at St. George’s University, where she explored molecular and behavioral aspects of ASD, and research technician roles in cardiovascular research at the University of Birmingham and the Academy of Athens.

Research Interest

Dr. Pantouli’s research interests span a spectrum of critical areas in biomedical science. She is passionate about exploring the neuropharmacology of social behavior disorders, with a focus on translational models for ASD and addiction. Her oncology research is centered on molecular mechanisms of tumor suppression, particularly the role of p53 in head and neck cancers. In immunology and virology, she is engaged in advancing personalized vaccine responses by decoding ethnic and cellular variability in immune reactions to viral pathogens. Across all areas, her goal is to identify novel therapeutic targets and improve clinical outcomes through precision medicine.

Award

While specific awards are not listed in her résumé, Dr. Pantouli’s consistent trajectory through prestigious research institutions, coupled with her leadership in high-impact projects funded by agencies like ARPA-H and her inclusion in peer-reviewed journals, demonstrates a sustained record of excellence and recognition by her scientific peers. Her nominations for publication in top-tier journals like Science and Biological Psychiatry further reflect her standing in the global research community.

Publications

Among Dr. Pantouli’s numerous contributions to scientific literature, the following are notable:

Pantouli, F., et al. (2025). COVID-19 Vaccination Enhances the Immunogenicity of Seasonal Influenza Vaccination in the Elderly. Vaccines, 13(5), 531. Cited by 3.

Pantouli, F., et al. (2024). Acute, Chronic and Conditioned Effects of Intranasal Oxytocin in the Mu Opioid Receptor Knockout Mouse Model of Autism. Neuropsychopharmacology. Cited by 9.

Pantouli, F., et al. (2021). Comparison of Morphine, Oxycodone and the Biased MOR Agonist SR-17018 in Mouse Models of Pain. Neuropharmacology, 185. Cited by 17.

Grim, T. W., et al., incl. Pantouli, F. (2020). G Protein-Biased Agonist Reverses Morphine Tolerance. Neuropsychopharmacology, 45. Cited by 26.

Morel, C., et al., incl. Pantouli, F. (2018). Nicotinic Receptors and Dopamine Cell Activity in Stress-Nicotine Interplay. Molecular Psychiatry, 23(7), 1597–1605. Cited by 35.

Acevedo-Canabal, A., Pantouli, F., et al. (2021). Pharmacological Variety in Opioid Analgesics. Reference Module in Biomedical Sciences. Cited by 4.

Pantouli, F., et al. (Submitted). Generation of Antigen-Specific Paired Heavy-Light Chain Antibody Sequences Using LLMs. Science. Under review.

Conclusion

Dr. Fani Pantouli exemplifies scientific excellence with her multidisciplinary research spanning neuroscience, immunology, and oncology. Her ability to deliver translational breakthroughs—whether in vaccine development, cancer modeling, or ASD treatment—makes her a standout candidate for the Best Researcher Award. Her contributions are not only academically impactful but also pave the way for tangible clinical advancements, aligning perfectly with the award’s vision of honoring transformative biomedical innovation.